KING HUSSEIN CANCER CENTER
🇯🇴Jordan
Clinical Trials
17
Active:0
Completed:8
Trial Phases
3 Phases
Phase 1:1
Phase 2:1
Not Applicable:9
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Not Applicable
9 (81.8%)Phase 1
1 (9.1%)Phase 2
1 (9.1%)Thoracic Paravertebral Block for Postoperative Pain Management After VATS
Not Applicable
Completed
- Conditions
- Pain, Postoperative
- Interventions
- Drug: 0.4 ml/kg of 0.5% bupivacaine
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- King Hussein Cancer Center
- Target Recruit Count
- 81
- Registration Number
- NCT06689358
- Locations
- 🇯🇴
King Hussein Cancer Center, Amman, Jordan
Clinical Trial Evaluating the Effectiveness of a Tattoo Compared to a Clip Applied to Axillary Lymph Nodes in Breast Cancer Patients Who Undergo SLNBx
Not Applicable
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- King Hussein Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT05836337
- Locations
- 🇯🇴
King Hussein Cancer Center, Amman, Al 'A̅şimah, Jordan
Extramedullary Acute Myeloid Leukemia (eAML): Retrospective Single Center Cohort Study, Clinicopathological, Molecular Analysis and Survival Outcomes
Completed
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2021-09-27
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- King Hussein Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT05057299
- Locations
- 🇯🇴
King Hussein Cancer Center, Amman, Jordan
Treatment Positioning in Vulvar Cancer Radiation Therapy
Recruiting
- Conditions
- Radiation Toxicity
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- King Hussein Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05014191
- Locations
- 🇯🇴
King Hussein Cancer Center, Amman, Jordan
Universal- Versus Guidelines-Directed Genetic Testing for Germline Pathogenic Variants Utilizing a Multi-Gene Panel for Inherited Cancers in Non-Western Society.
Completed
- Conditions
- Genetic Predisposition
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- King Hussein Cancer Center
- Target Recruit Count
- 3000
- Registration Number
- NCT04920513
- Locations
- 🇯🇴
King Hussein Cancer Center, Amman, Jordan
- Prev
- 1
- 2
- 3
- 4
- Next
News
Real-World Study Affirms Ribociclib's Efficacy in HR+/HER2- Metastatic Breast Cancer
A retrospective study confirms that ribociclib combined with endocrine therapy is effective for HR+/HER2- metastatic breast cancer in real-world settings.